SCHEMBL257244

SCHEMBL257244

COC(=O)c1ccc(Br)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SLC6A3 Q01959 2/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
HSD17B10 Q99714 2/20 0.48
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
GAA P10253 3/20 0.47
GPR27 Q9NS67 1/20 0.47
CLK1 P49759 1/20 0.47
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 4/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29827082 1.00 NR4A2 (0.51) NR4A2L3MBTL1SLC6A3KDM4EALDH1A1
SCHEMBL28963406 0.86 SLC6A3 (0.49) NR4A2L3MBTL1SLC6A3ALDH1A1MAPT
SCHEMBL30361998 0.85 ALDH1A1 (0.59) NR4A2L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL392403 0.85 ALDH1A1 (0.59) NR4A2L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL26647783 0.84 KDM4E (0.48) NR4A2L3MBTL1SLC6A3KDM4EALDH1A1
SCHEMBL21591115 0.84 GPR27 (0.52) KDM4EALDH1A1MAPTHSD17B10GFER
SCHEMBL27026753 0.84 NPC1 (0.60) L3MBTL1ALDH1A1MAPTHSD17B10GFER
SCHEMBL30108636 0.83 STAT3 (0.48) NR4A2L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL29688415 0.83 PTGDR2 (0.50) KDM4EALDH1A1MAPTHSD17B10GFER
SCHEMBL1824265 0.83 PTGDR2 (0.50) KDM4EALDH1A1MAPTHSD17B10GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2024-01-30 US claimed
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-06-29 US claimed
US-20210137901-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2021-05-13 US claimed
EP-2516479-B1 NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS BASF CORP (US) 2016-04-20 EP claimed
EP-2516479-A2 NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS BASF Corporation (US) 2012-10-31 EP claimed
CN-102762602-A New internal and external donor compounds for olefin polymerization catalysts BASF CORP 2012-10-31 CN claimed
US-8211819-B2 Internal and external donor compounds for olefin polymerization catalysts BASF CORPORATION (US) 2012-07-03 US claimed
WO-2011084691-A2 NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS BASF CORPORATION (US) 2011-07-14 WO claimed
US-20110152481-A1 Internal and external donor compounds for olefin polymerization catalysts BASF CATALYSTS LLC (US) 2011-06-23 US claimed
EP-4565565-B1 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES NXERA PHARMA UK LTD (GB) 2026-05-27 EP disclosed
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
WO-1999052857-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1999-10-21 WO disclosed
CN-1222145-A Substituted benzamide derivatives and their use as anticonvulsants SMITHKLINE BEECHAM PLC (GB) 1999-07-07 CN disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed
EP-0906283-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-04-07 EP disclosed
WO-1997048683-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1997-12-24 WO disclosed
US-4916145-A PLATELET ACTIVATING FACTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 1990-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A NR4A2 3084/4885L3MBTL1 3538/4885SLC6A3 4018/4885
US-20210137901-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A NR4A2 3084/4885L3MBTL1 3538/4885SLC6A3 4018/4885
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A NR4A2 3084/4885L3MBTL1 3538/4885SLC6A3 4018/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR NR4A2 2777/4885L3MBTL1 1493/4885SLC6A3 475/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT NR4A2 2151/4885L3MBTL1 991/4885SLC6A3 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.